Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis
- PMID: 35671707
- PMCID: PMC9808712
- DOI: 10.1159/000525001
Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis
Abstract
Introduction: Within 30 years, 20-50% of IgA nephropathy (IgAN) patients progress to end-stage kidney disease (ESKD). Identifying these patients can be difficult since renal function may deteriorate after being stable for years. The International IgAN Risk Prediction tool (IgAN-RPT) combines histologic lesions and clinical risk factors to predict renal outcome up to 5 or 7 years of follow-up. The clinical value beyond 7 years is unknown and microhematuria data has not been assessed.
Methods: We studied the long-term renal outcome of 95 Swedish IgAN patients from the derivation cohort for the IgAN-RPT. The median follow-up was 11.2 years. Microhematuria at baseline was defined as high-degree by microscopy measurement of >10 red blood cell/high-power field of view or urine dipstick grading of 2-3. Primary outcome was defined as a 50% decrease in estimated glomerular filtration rate or ESKD.
Results: The mean predicted 5-year risk for increasing quartiles was 0.95%, 2.57%, 5.88%, and 23.31% and the observed 5-year-outcome was 0%, 0%, 0%, and 33.33%. During continued follow-up, 0%, 4.2%, 21.7%, and 75.0% of patients reached the primary outcome. ROC curve analysis identified the 5-year risk thresholds of under 4% and over 11% for very low and very high-risk patients, respectively. High-degree microhematuria was not significantly associated with renal outcome (p = 0.14).
Conclusions: The IgAN-RPT identifies long-term high- and low-risk patients, which can guide decisions on the frequency of clinical control visits and the selection of patients for clinical trials. Patients with intermediate risk remain a clinical challenge with an urgent need for novel biomarkers and treatments. Microhematuria could be a valuable marker of inflammatory activity, but measurement needs to be standardized for implementation in risk prediction tools.
Keywords: Hematuria; IgA nephropathy; Prediction model; Prognosis; Progression.
© 2022 The Author(s). Published by S. Karger AG, Basel.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures




Similar articles
-
Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients.Clin Kidney J. 2023 Dec 4;16(Suppl 2):ii19-ii27. doi: 10.1093/ckj/sfad232. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38053974 Free PMC article. Review.
-
Persistent Hematuria and Kidney Disease Progression in IgA Nephropathy: A Cohort Study.Am J Kidney Dis. 2020 Jul;76(1):90-99. doi: 10.1053/j.ajkd.2019.11.008. Epub 2020 Mar 18. Am J Kidney Dis. 2020. PMID: 32197881
-
Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients.Nephrol Dial Transplant. 2016 Jan;31(1):80-6. doi: 10.1093/ndt/gfv232. Epub 2015 Jun 4. Nephrol Dial Transplant. 2016. PMID: 26047632
-
Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients.Am J Kidney Dis. 2018 Sep;72(3):371-380. doi: 10.1053/j.ajkd.2018.01.043. Epub 2018 Mar 17. Am J Kidney Dis. 2018. PMID: 29555434
-
Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis.Ren Fail. 2021 Dec;43(1):488-499. doi: 10.1080/0886022X.2021.1879852. Ren Fail. 2021. PMID: 33685345 Free PMC article.
Cited by
-
Machine learning-based diagnosis and prognosis of IgAN: A systematic review and meta-analysis.Heliyon. 2024 Jun 14;10(12):e33090. doi: 10.1016/j.heliyon.2024.e33090. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 38988582 Free PMC article. Review.
-
Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients.Clin Kidney J. 2023 Dec 4;16(Suppl 2):ii19-ii27. doi: 10.1093/ckj/sfad232. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38053974 Free PMC article. Review.
-
Development and validation of personalized risk prediction models for patients with IgA nephropathy: a nationwide multicenter cohort study.J Nephrol. 2025 Jul;38(6):1573-1582. doi: 10.1007/s40620-025-02338-x. Epub 2025 Jul 11. J Nephrol. 2025. PMID: 40643794
-
Autoinflammatory diseases and the kidney.Immunol Res. 2023 Aug;71(4):578-587. doi: 10.1007/s12026-023-09375-3. Epub 2023 Mar 29. Immunol Res. 2023. PMID: 36991303 Free PMC article. Review.
-
Validation of 2 Prognostic Models to Predict Renal Allograft Outcome After IgA Nephropathy Recurrence.Kidney Int Rep. 2025 Apr 21;10(7):2323-2333. doi: 10.1016/j.ekir.2025.04.028. eCollection 2025 Jul. Kidney Int Rep. 2025. PMID: 40677345 Free PMC article.
References
-
- McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26((2)):414–30. - PubMed
-
- Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347((10)):738–48. - PubMed
-
- Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004;66((3)):905–8. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous